{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:24:54Z","timestamp":1792635894167,"version":"4.5.0"},"reference-count":74,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Plasmodium spp. is the etiological agent of malaria, a life-threatening parasitic disease transmitted by infected mosquitoes. Malaria remains a major global health challenge, particularly in endemic regions. Over the years, various vaccine candidates targeting different stages of Plasmodium parasite life-cycle have been explored, including subunit vaccines, vectored vaccines, and whole organism vaccines with Mosquirix, a vaccine based on a recombinant protein, as the only currently approved vaccine for Plasmodium falciparum malaria. Despite the aforementioned notable progress, challenges such as antigenic diversity, limited efficacy, resistant parasites escaping protective immunity and the need for multiple doses have hindered the development of a highly efficacious malaria vaccine. The recent success of mRNA-based vaccines against SARS-CoV-2 has sparked renewed interest in mRNA vaccine platforms. The unique mRNA vaccine features, including their potential for rapid development, scalability, and flexibility in antigen design, make them a promising avenue for malaria vaccine development. This review provides an overview of the malaria vaccines\u2019 evolution from the past towards the mRNA vaccine era and highlights their advantages in overcoming the limitations of previous malaria vaccine candidates.<\/jats:p>","DOI":"10.3390\/vaccines11091452","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T02:14:50Z","timestamp":1693793690000},"page":"1452","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Malaria Vaccines: From the Past towards the mRNA Vaccine Era"],"prefix":"10.3390","volume":"11","author":[{"given":"Maria E.","family":"Tsoumani","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, University of West Attica, 12243 Aigaleo, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2136-819X","authenticated-orcid":false,"given":"Chrysa","family":"Voyiatzaki","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of West Attica, 12243 Aigaleo, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0946-3717","authenticated-orcid":false,"given":"Antonia","family":"Efstathiou","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of West Attica, 12243 Aigaleo, Greece"},{"name":"Immunology of Infection Group, Department of Microbiology, Hellenic Pasteur Institute, 11521 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2023, July 21). Malaria. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/malaria."},{"key":"ref_2","unstructured":"Centers for Disease Control and Prevention (CDC) (2023, July 21). Malaria, Available online: https:\/\/www.cdc.gov\/malaria\/about\/faqs.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S319","DOI":"10.1016\/j.amepre.2015.09.011","article-title":"The March toward Malaria Vaccines","volume":"49","author":"Hoffman","year":"2015","journal-title":"Am. J. Prev. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1026052","DOI":"10.3389\/fimmu.2022.1026052","article-title":"Exploring in vitro expression and immune potency in mice using mRNA encoding the Plasmodium falciparum malaria antigen, CelTOS","volume":"13","author":"Waghela","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/10409230290771447","article-title":"DNA vaccine against malaria: A long way to go","volume":"37","author":"Tuteja","year":"2002","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1080\/21645515.2021.1947762","article-title":"Novel malaria vaccines","volume":"17","author":"Laurens","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s43856-021-00030-2","article-title":"Recent clinical trials inform the future for malaria vaccines","volume":"1","author":"Kurtovic","year":"2021","journal-title":"Commun. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/2121492a0","article-title":"Active immunization of chicks against Plasmodium gallinaceum by inactivated homologous sporozoites and erythrocytic parasites","volume":"212","author":"Richards","year":"1966","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/339409","article-title":"Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites","volume":"185","author":"Hoffman","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e89154","DOI":"10.1172\/jci.insight.89154","article-title":"Protection against Plasmodium falciparum malaria by PfSPZ Vaccine","volume":"2","author":"Epstein","year":"2017","journal-title":"JCI Insight"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1126\/science.1241800","article-title":"Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine","volume":"341","author":"Seder","year":"2013","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nm.4110","article-title":"Protection against malaria at 1 year and immune correlates following PfSPZ vaccination","volume":"22","author":"Ishizuka","year":"2016","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-021-01470-y","article-title":"Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: A double-blind, randomized, placebo-controlled phase 2 trial","volume":"27","author":"Oneko","year":"2021","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41564-021-00982-0","article-title":"Malaria vaccine roller coaster","volume":"6","author":"Nkumama","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","article-title":"Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: A randomised, double-blind phase 1 trial","volume":"17","author":"Sissoko","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1093\/cid\/ciz1152","article-title":"Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ vaccine in Tanzanian Adults","volume":"71","author":"Jongo","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"eabj3776","DOI":"10.1126\/scitranslmed.abj3776","article-title":"A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria","volume":"14","author":"Sirima","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1073\/pnas.1220360110","article-title":"Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity","volume":"110","author":"Bijker","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/0140-6736(93)93058-9","article-title":"Long-term malaria prophylaxis with weekly mefloquine","volume":"341","author":"Lobel","year":"1993","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101579","DOI":"10.1016\/j.eclinm.2022.101579","article-title":"PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial","volume":"52","author":"Coulibaly","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.1016\/j.vaccine.2015.09.096","article-title":"Progress with P. falciparum sporozoite based malaria vaccines","volume":"33","author":"Richie","year":"2015","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41541-022-00473-1","article-title":"Efficacy, T cell activation and antibody responses in accelerated Plasmodium falciparum sporozoite chemoprophylaxis vaccine regimens","volume":"7","author":"Ibanez","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/14760584.2017.1341835","article-title":"Genetically attenuated malaria parasites as vaccines","volume":"16","author":"Vaughan","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"eaad9099","DOI":"10.1126\/scitranslmed.aad9099","article-title":"Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects","volume":"9","author":"Kublin","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"eabn9709","DOI":"10.1126\/scitranslmed.abn9709","article-title":"A genetically-engineered Plasmodium falciparum parasite vaccine provides protection from controlled human malaria infection","volume":"14","author":"Murphy","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"eaaz5629","DOI":"10.1126\/scitranslmed.aaz5629","article-title":"A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1","volume":"12","author":"Roestenberg","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s41182-023-00516-w","article-title":"Malaria vaccines: The 60-year journey of hope and final success\u2014lessons learned and future prospects","volume":"51","year":"2023","journal-title":"Trop. Med. Health"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41590-018-0228-6","article-title":"Malaria prevention: From immunological concepts to effective vaccines and protective antibodies","volume":"19","author":"Cockburn","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"111425","DOI":"10.1016\/j.molbiopara.2021.111425","article-title":"The role of different components of the immune system against Plasmodium falciparum malaria: Possible contribution towards malaria vaccine development","volume":"246","author":"Mandala","year":"2021","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"The RTS,S Clinical Trials Partnership (2011). First Results of Phase 3 Trial of RTS,S\/AS01 Malaria Vaccine in African Children. N. Engl. J. Med., 365, 1863\u20131875.","DOI":"10.1056\/NEJMoa1102287"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"R203","DOI":"10.1016\/j.cub.2023.03.017","article-title":"Magazine New beginnings for malaria research","volume":"33","author":"Gross","year":"2023","journal-title":"Curr. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S1473-3099(22)00273-0","article-title":"Efficacy of RTS,S\/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5\u201317 months in Ghana and Kenya: An open-label, phase 2b, randomised controlled trial","volume":"22","author":"Samuels","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"srep46621","DOI":"10.1038\/srep46621","article-title":"Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine","volume":"7","author":"Collins","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S1473-3099(22)00139-6","article-title":"COVID-19 vaccine results might inform malaria vaccine strategies","volume":"22","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: A randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: A phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1098\/rstb.2011.0091","article-title":"Vaccines against malaria","volume":"366","author":"Hill","year":"2011","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"286re5","DOI":"10.1126\/scitranslmed.aaa2373","article-title":"Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults","volume":"7","author":"Ogwang","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3389\/fimmu.2019.02412","article-title":"A viral-vectored multi-stage malaria vaccine regimen with protective and transmission-blocking efficacies","volume":"10","author":"Yusuf","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0140-6736(03)15267-1","article-title":"Malaria vaccine developments","volume":"363","author":"Moorthy","year":"2004","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Palacpac, N.M.Q., Ntege, E., Yeka, A., Balikagala, B., Suzuki, N., Shirai, H., Yagi, M., Ito, K., Fukushima, W., and Hirota, Y. (2013). Phase 1b Randomized Trial and Follow-Up Study in Uganda of the Blood-Stage Malaria Vaccine Candidate BK-SE36. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0064073"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"978591","DOI":"10.3389\/fimmu.2022.978591","article-title":"Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children","volume":"13","author":"Bougouma","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"105203","DOI":"10.1016\/j.micpath.2021.105203","article-title":"How can we develop an effective subunit vaccine to achieve successful malaria eradication?","volume":"160","author":"Pirahmadi","year":"2021","journal-title":"Microb. Pathog."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/d41586-021-00019-w","article-title":"How COVID unlocked the power of RNA vaccines","volume":"589","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1517\/17460441.2015.996128","article-title":"Vaccines \u201con demand\u201d: Science fiction or a future reality","volume":"10","author":"Ulmer","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.4161\/hv.25611","article-title":"Making vaccines \u201con demand\u201d","volume":"9","author":"Einck","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4161\/hv.3.2.3833","article-title":"Reduced production of RNA transcripts from individual DNA plasmids given in a multivalent DNA vaccine formula","volume":"3","author":"Bacon","year":"2007","journal-title":"Hum. Vaccin."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.exppara.2009.02.010","article-title":"Plasmodium: Mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity","volume":"122","author":"Sedegah","year":"2009","journal-title":"Exp. Parasitol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1006\/bbrc.1999.1050","article-title":"Codon optimization effect on translational efficiency of DNA vaccine in mammalian cells: Analysis of plasmid DNA encoding a CTL epitope derived from microorganisms","volume":"261","author":"Nagata","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"9867","DOI":"10.1073\/pnas.90.21.9867","article-title":"Gene sequence tags from Plasmodium falciparum genomic DNA fragments prepared by the \u201cgenease\u201d activity of mung bean nuclease","volume":"90","author":"Reddy","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.4049\/jimmunol.172.9.5561","article-title":"Induction in Humans of CD8+ and CD4+ T Cell and Antibody Responses by Sequential Immunization with Malaria DNA and Recombinant Protein","volume":"172","author":"Wang","year":"2004","journal-title":"J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1006\/bbrc.2000.2558","article-title":"Direct immunization of malaria DNA vaccine into the liver by gene gun protects against lethal challenge of Plasmodium berghei sporozoite","volume":"271","author":"Yoshida","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00394-008-0717-8","article-title":"The anti-atherosclerotic effect of olive leaf extract is related to suppressed inflammatory response in rabbits with experimental atherosclerosis","volume":"47","author":"Wang","year":"2008","journal-title":"Eur. J. Nutr."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1128\/CVI.00185-15","article-title":"Evaluation of the impact of codon optimization and N-linked glycosylation on functional immunogenicity of Pfs25 DNA vaccines delivered by in vivo electroporation in preclinical Studies in mice","volume":"22","author":"Datta","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6868","DOI":"10.1016\/j.vaccine.2010.08.019","article-title":"Selection and identification of malaria vaccine target molecule using bioinformatics and DNA vaccination","volume":"28","author":"Shuaibu","year":"2010","journal-title":"Vaccine"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Fotoran, W.L., da Silva, J.R., Glitz, C., Ferreira, L.C.d.S., and Wunderlich, G. (2023). Establishment of an Antiplasmodial Vaccine Based on PfRH5-Encoding RNA Replicons Stabilized by Cationic Liposomes. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041223"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.trstmh.2004.03.007","article-title":"A potential disruptive technology in vaccine development: Gene-based vaccines and their application to infectious diseases","volume":"98","author":"Kaslow","year":"2004","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_58","first-page":"244","article-title":"Non-viral amplification systems for gene transfer: Vectors based on alphaviruses","volume":"1","author":"Smerdou","year":"1999","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41541-021-00345-0","article-title":"Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice","volume":"6","author":"Mallory","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1038\/s41467-018-05041-7","article-title":"Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection","volume":"9","author":"Garcia","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41541-022-00577-8","article-title":"mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum","volume":"7","author":"Hayashi","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Bergmann-Leitner, E.S., Chaudhury, S., Steers, N.J., Sabato, M., Delvecchio, V., Wallqvist, A.S., Ockenhouse, C.F., and Angov, E. (2013). Computational and Experimental Validation of B and T-Cell Epitopes of the In Vivo Immune Response to a Novel Malarial Antigen. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071610"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Sedegah, M., Hollingdale, M.R., Ganeshan, H., Belmonte, M., Huang, J., Belmonte, A., Inoue, S., Velasco, R., Hickey, B., and Teneza-Mora, N. (2021). IMRAS-Immunization with radiationattenuated Plasmodium falciparum sporozoites by mosquito bite: Cellular immunity to sporozoites, CSP, AMA1, TRAP and CelTOS. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0256396"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Bergmann-Leitner, E.S., Mease, R.M., de la Vega, P., Savranskaya, T., Polhemus, M., Ockenhouse, C., and Angov, E. (2010). Immunization with pre-erythrocytic antigen CelTOS from plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012294"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2011.06.053","article-title":"Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS","volume":"29","author":"Legler","year":"2011","journal-title":"Vaccine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e00498-16","DOI":"10.1128\/IAI.00498-16","article-title":"The Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites as a candidate for preerythrocytic and transmission-blocking vaccines","volume":"85","author":"Espinosa","year":"2017","journal-title":"Infect. Immun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41541-023-00679-x","article-title":"A mosquito AgTRIO mRNA vaccine contributes to immunity against malaria","volume":"8","author":"Chuang","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41590-023-01562-6","article-title":"mRNA vaccine against malaria tailored for liver-resident memory T cells","volume":"24","author":"Ganley","year":"2023","journal-title":"Nat. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41586-020-2220-1","article-title":"Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria","volume":"582","author":"Raj","year":"2020","journal-title":"Nature"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14760584.2022.2011226","article-title":"Will the mRNA vaccine platform be the panacea for the development of vaccines against antimicrobial resistant (AMR) pathogens?","volume":"21","author":"Chen","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-bioeng-110220-031722","article-title":"Current Developments and Challenges of mRNA Vaccines","volume":"24","author":"Chen","year":"2022","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1039\/D2NH00289B","article-title":"Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases","volume":"8","author":"Chung","year":"2022","journal-title":"Nanoscale Horizons"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: Principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_74","unstructured":"Safety and Immune Responses after Vaccination With an Investigational RNA-based Vaccine Against Malaria (2023, August 18). ClinicalTrials.gov, Identifier: NCT05581641, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05581641?term=BNT165-01&draw=2&rank=1."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/9\/1452\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:45:51Z","timestamp":1760129151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/9\/1452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":74,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["vaccines11091452"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11091452","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]}}}